Given the widespread overexpression of GPX4 across multiple cancer types, leveraging Cu2+ and erastin to induce autophagy‐dependent GPX4 degradation and thereby sensitize cancer cells to ferroptosis has emerged as a promising therapeutic paradigm that may surpass conventional approaches. This evidence concerns the gene GPX4 and cancer.